Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
8-24-2021

Convergent antibody responses to the SARS-CoV-2 spike protein
in convalescent and vaccinated individuals
Elaine C Chen
Emma S Winkler
Rita E Chen
Michael S Diamond
et al

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Article

Convergent antibody responses to the SARS-CoV-2
spike protein in convalescent and vaccinated
individuals
Graphical abstract

Authors
Elaine C. Chen, Pavlo Gilchuk,
Seth J. Zost, ..., Curtis A. Thorne,
Michael S. Diamond, James E. Crowe, Jr.

Correspondence
james.crowe@vumc.org

In brief
Chen et al. describe neutralizing and nonneutralizing public antibodies elicited to
SARS-CoV-2 spike in vaccinated and
naturally infected individuals. Germlinerevertant forms of some public
clonotypes bind efficiently to spike
protein, suggesting common germlineencoded properties for recognition.

Highlights
d

Public clonotypes are shared among SARS-CoV-2vaccinated and -infected individuals

d

Group 3 antibodies share the same binding site as CR3022
but neutralize variants

d

Germline-revertant forms of public clonotypes bind efficiently
to spike protein

d

Public clonotype responses inform research on new viral
variants of concern

Chen et al., 2021, Cell Reports 36, 109604
August 24, 2021 ª 2021 The Author(s).
https://doi.org/10.1016/j.celrep.2021.109604

ll

ll
OPEN ACCESS

Article

Convergent antibody
responses to the SARS-CoV-2 spike
protein in convalescent and vaccinated individuals
Elaine C. Chen,1 Pavlo Gilchuk,2 Seth J. Zost,2 Naveenchandra Suryadevara,2 Emma S. Winkler,3,4 Carly R. Cabel,5,10
Elad Binshtein,2 Rita E. Chen,3,4 Rachel E. Sutton,2 Jessica Rodriguez,2 Samuel Day,2 Luke Myers,2 Andrew Trivette,2
Jazmean K. Williams,6 Edgar Davidson,6 Shuaizhi Li,9 Benjamin J. Doranz,6 Samuel K. Campos,9,10 Robert H. Carnahan,2
Curtis A. Thorne,5,10 Michael S. Diamond,3,4,7 and James E. Crowe, Jr.1,2,8,11,*
1Department

of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA
3Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA
4Department of Medicine, Washington University School of Medicine, Saint Louis, MO 63110, USA
5Department of Cellular & Molecular Medicine, University of Arizona College of Medicine, Tucson, AZ 85724, USA
6Integral Molecular, Inc., Philadelphia, PA 19104, USA
7Department of Molecular Microbiology, Washington University School of Medicine, Saint Louis, MO 63110, USA
8Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA
9Department of Immunobiology, University of Arizona College of Medicine, Tucson, AZ 85724, USA
10Cancer Biology Graduate Interdisciplinary Program, University of Arizona, Tucson, AZ 85724, USA
11Lead contact
*Correspondence: james.crowe@vumc.org
https://doi.org/10.1016/j.celrep.2021.109604
2Vanderbilt

SUMMARY

Unrelated individuals can produce genetically similar clones of antibodies, known as public clonotypes,
which have been seen in responses to different infectious diseases, as well as healthy individuals. Here
we identify 37 public clonotypes in memory B cells from convalescent survivors of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection or in plasmablasts from an individual after vaccination with
mRNA-encoded spike protein. We identify 29 public clonotypes, including clones recognizing the receptorbinding domain (RBD) in the spike protein S1 subunit (including a neutralizing, angiotensin-converting
enzyme 2 [ACE2]-blocking clone that protects in vivo) and others recognizing non-RBD epitopes that bind
the S2 domain. Germline-revertant forms of some public clonotypes bind efficiently to spike protein, suggesting these common germline-encoded antibodies are preconfigured for avid recognition. Identification of
large numbers of public clonotypes provides insight into the molecular basis of efficacy of SARS-CoV-2 vaccines and sheds light on the immune pressures driving the selection of common viral escape mutants.
INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
is the causative agent of COVID-19 and the ongoing worldwide
pandemic. The spike (S) protein is the principal antigen recognized by the protective antibody response against SARS-CoV2 (Jiang et al., 2020; Krammer, 2020). The S protein is cleaved
into S1, which includes the receptor-binding domain (RBD) and
the N-terminal domain (NTD), and S2, contains the fusion peptide and heptad repeats HR1 and HR2 and mediates fusion between virus and host cell membrane (Bosch et al., 2003; Tortorici
and Veesler, 2019). SARS-CoV-2 and SARS-CoV-1 share
approximately 80% amino acid sequence identity, and both
use human angiotensin-converting enzyme 2 (ACE2) as an entry
receptor through binding mediated by the RBD (Hoffmann et al.,
2020; Li et al., 2003; Wan et al., 2020).
Monoclonal antibodies (mAbs) targeting the SARS-CoV-2 S
protein have been a focus for development of medical counter-

measures against COVID-19. Many studies have identified antibodies to the S1 and S2 regions on the S protein, with the majority
of neutralizing antibodies targeting the RBD in S1 and inhibiting
ACE2 binding (Liu et al., 2020; Robbiani et al., 2020; Seydoux
et al., 2020; Wec et al., 2020; Zost et al., 2020b). Multiple RBDspecific mAbs have been developed as monotherapies or cocktail
therapeutics, and three have received Emergency Use Authorization (EUA) in the United States.
In recent years, public B cell clonotypes have been identified in
the human antibody repertoires formed in response to diverse viruses, including Ebola (Cohen-Dvashi et al., 2020; Davis et al.,
2019; Ehrhardt et al., 2019), influenza (Joyce et al., 2016; Pappas
et al., 2014; Zost et al., 2021; Sui et al., 2009; Wheatley et al.,
2015), human immunodeficiency virus 1 (HIV-1) (Setliff et al.,
2018; Williams et al., 2015; Wu et al., 2011; Zhou et al., 2015),
hepatitis C (Bailey et al., 2017; Giang et al., 2012), SARS-CoV2 (Dong et al., 2021; Nielsen et al., 2020; Yuan et al., 2020a), respiratory syncytial virus (Mukhamedova et al., 2021), and in
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healthy individuals (Briney et al., 2019; Soto et al., 2019). These
studies reveal a convergence of B cell selection resulting in
circulating B cells clones with genetically similar antigen receptor genes in multiple individuals. The selection of public B cell
clonotypes often has a structural basis mediated by low-affinity
recognition of virus surface antigens by unmutated germline-encoded naive B cell receptors that are preconfigured for binding
and cell activation. Public clonotypes are of great interest,
because the understanding of viral epitopes that commonly
induce antibodies in humans has implications for predicting the
most common responses to vaccines in large populations.
Several efforts have characterized public clonotypes in the
response to SARS-CoV-2, with most work focused on neutralizing public clonotypes (Dong et al., 2021; Robbiani et al.,
2020; Tan et al., 2021; Yuan et al., 2020a) that target the S1 protein RBD and NTD domains. However, it is less clear if public clonotypes are directed to other sites on the S trimer, such as the S2
domain. Epitopes on the S2 domain may be of interest, because
these sites may be more conserved than those in RBD in
different strains of coronavirus as a result of functional constraints associated with the viral fusion mechanism. In this study,
we identified 37 total public clonotypes, 27 of which are shared
between vaccinated and convalescent individuals. We found
that shared clonotypes comprise a substantial proportion of
the elicited human B cell response to the S trimer. We also
compared the response following infection or mRNA vaccination
to investigate the genetic basis for the efficacy of mRNA vaccines in the population. These data show that many clonotypes
are shared between convalescent and vaccinated individuals.
RESULTS
Identification of public clonotypes
We first collected antibody variable gene sequences for SARSCoV-2 human mAbs from existing publications that reported
mAbs from individuals with a history of SARS-CoV-2 infection
(Brouwer et al., 2020; Cao et al., 2020; Kreer et al., 2020; Liu
et al., 2020; Robbiani et al., 2020; Rogers et al., 2020; Seydoux
et al., 2020; Wec et al., 2020; Zost et al., 2020b). This search
identified a panel of 2,865 paired heavy and light chain variable
gene sequences. We clustered all sequences by binning the
clones based on the inferred immunoglobulin heavy variable
(IGHV) gene, immunoglobulin heavy joining (IGHJ) gene, and
the amino acid length of the heavy chain complementarity determining region 3 (CDRH3). These sequences then were clustered
according to 70% nucleotide sequence identity in the DNA
sequence encoding the CDRH3. Next, the sequences were
binned further based on the inferred immunoglobulin light variable gene (IGLV or IGKV) and immunoglobulin light joining
(IGLJ or IGKJ) genes. Clusters meeting these similarity criteria
in both heavy and light chains with sequences originating from
two or more individuals were deemed public clonotypes. Eleven
public clonotypes were identified in the repertoires of subjects
with prior natural infection (Figures 1A–1C), and these clones
are encoded by a variety of heavy and light chain variable genes.
Of the 11 public clonotypes identified, 5 of the heavy chain genes
have been reported previously to encode potently neutralizing
SARS-CoV-2 antibodies that bind to the RBD: IGHV3-53 (Yuan
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et al., 2020a), IGHV1-58 (Dong et al., 2021), IGHV3-30, IGHV330-3 (Robbiani et al., 2020), and IGHV3-66 (Yuan et al., 2020a).
Three have not been reported: IGHV1-69, IGHV4-59, and
IGHV3-7. IGHV3-53 and IGHV3-66 are commonly observed in
antibodies in SARS-CoV-2 patients (Robbiani et al., 2020)
because the germline gene segments encode amino acid motifs
that are preconfigured for RBD binding (Yuan et al., 2020a).
IGHV1-58 also commonly encodes antibodies that neutralize
SARS-CoV-2, because this germline gene segment encodes
motifs that mediate binding to the S protein (Dong et al., 2021).
Notably, IGHV1-58 encodes the mAb COV2-2196, which is the
basis for one of the two antibodies in a cocktail currently in phase
III clinical trials (Dong et al., 2021; Zost et al., 2020a). Clonally
expanded B cell populations containing potently neutralizing antibodies encoded by IGHV3-30 also have been found in multiple
individuals (Robbiani et al., 2020). However, the role of IGHV169, IGHV4-59, and IGHV3-7 public clonotypes in SARS-CoV-2
responses remains unknown. In this paper, for clarity, we designated public clonotypes incorporating these additional three VH
gene segments as members of group 1, 2, or 3 mAbs, respectively (Figures 1C–1E). Group 1 is shared by two donors from
the cohort we studied and includes mAbs COV2-2002 and
COV2-2333. Group 2 is shared by a donor from our group and
a previously described donor IDCnC2 (Kreer et al., 2020) and includes antibodies COV2-2164 and CnC2t1p1_B10. Lastly,
group 3 is shared by a donor from our group and a previously
described donor COV107 (Robbiani et al., 2020) and includes antibodies COV2-2531 and C126 (Figures 1C–1E). cDNAs for the
antibody variable genes encoding each of the six antibodies
from the three groups of public clonotypes were synthesized
and cloned into an IgG1 expression vector, as previously
described (Gilchuk et al., 2020).
Functional properties of identified public clonotype
antibodies
To examine the binding properties of antibodies in these three
new SARS-CoV-2 public clonotypes, we tested six recombinant
purified antibodies, two for each public clonotype, for binding to
recombinant stabilized trimeric prefusion ectodomain of the
SARS-CoV-2 S protein (S6Pecto), SARS-CoV-2 RBD, or recombinant stabilized trimeric prefusion ectodomain of the SARS-CoV1 S protein (S2Pecto) proteins by ELISA (Figure S1). The two
group 1 antibodies, COV2-2002 and COV2-2333, did not bind
to SARS-CoV-2 RBD, but both bound to SARS-CoV-2 S6Pecto
and SARS-CoV-1 S2Pecto proteins. However, they did not saturate in binding to SARS-CoV-1 S2Pecto at the maximum concentration tested (400 ng/mL), indicating relatively weak binding to
recombinant SARS-CoV-1 S2Pecto. Group 2 antibodies, which
include COV2-2164 and CnC2t1p1_B10, did not bind to SARSCoV-2 RBD, but both bound to SARS-CoV-2 S6Pecto and
SARS-CoV-1 S2Pecto proteins. Group 3 antibodies, which
include COV2-2531 and C126, bound to SARS-CoV-2 S6Pecto
and SARS-CoV-2 RBD proteins (Figures 2A and 2H). Antibodies
from group 3 did not bind SARS-CoV-1 S2Pecto.
We hypothesized that group 1 and 2 antibodies might bind the
S2 domain of the S trimer; SARS-CoV-2 infection can elicit antibodies that recognize cross-reactive epitopes on the S2 domain
(Ladner et al., 2021). Antibodies were tested for binding against
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Figure 1. Sequence characteristics of monoclonal antibodies to SARS-CoV-2
(A) Available sequences of mAbs to SARS-CoV-2 from multiple publications were obtained from public databases. Numbers inside each box represent the
number of sequences with the indicated gene usage. Colored outlining boxes represent public clonotypes that are shared between the individuals listed in the key
to the right side. The heatmap is color coded so that red represents a higher number of sequences using the corresponding genes, and blue represents a lower
number of sequences using the corresponding genes.
(B) CDR3 sequences of the heavy and light chains of each of the remaining eight public clonotypes are shown. Dashes represent amino acids that differed in the
public clonotype. Each box color correlates to the public clonotypes in (A) and (C).
(C) A Venn diagram illustrating all of the public clonotypes identified between naturally infected individuals. The colored boxes in the Venn diagram overlaps
represent the public clonotypes identified in (A). Novel public clonotypes, designated as groups 1, 2, or 3, are highlighted in the purple, pink, or orange overlaps,
respectively.
(D) Multiple sequence alignments of the heavy chain sequences for groups 1, 2, or 3 to their respective inferred germline genes IGHV 3-07/IGHJ4, IGHV1-69/
IGHJ4, or IGHV4-59/IGHJ3. The CDRH3 sequence is highlighted in dark blue.
(E) Multiple sequence alignments of the light chain sequences for groups 1, 2, or 3 to their respective inferred germline genes IGLV3-01/IGLJ3, IGKV3-11/IGKJ4,
or IGHV3-01/IGLJ2. The CDRL3 sequence is highlighted in light blue.
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the S2 domain of SARS-CoV-2 S expressed on HEK293T cells.
This experiment showed that group 1 and 2 antibodies bound
to S2 in a dose-dependent manner (Figures 2D, 2F, and 2H),
and revealed that public clonotypes can be elicited to the S2
domain of the S trimer.
Antibodies from each group then were tested for neutralizing
activity using a previously described real-time cell analysis
(RTCA) assay that measures cellular impedance (Gilchuk et al.,
2020; Zost et al., 2020b). We used recombinant, infectious vesicular stomatitis virus (VSV) expressing the S proteins from SARSCoV-2 (WA1/2019 strain), SARS-CoV-2/D614G, or SARS-CoV-1
(Urbani strain) (Figure S1). In addition, we used authentic SARSCoV-2 (WA1/2019) virus and Calu3 cell monolayer cultures, and
neutralization was measured by staining for double-stranded
RNA, which is produced in the cytoplasm in virus-infected cells
(Figure S2). Group 3 mAb COV2-2531 neutralized SARS-CoV-2
(VSV-SARS-CoV-2 and VSV-SARS-CoV-2/D614G) (Figures 2B,
2C, and 2H) and authentic SARS-CoV-2, but not SARS-CoV-1.
In contrast, another group 3 mAb, C126, partially neutralized
the SARS-CoV-2/D614G variant but did not neutralize the wildtype (WT) VSV-SARS-CoV-2, VSV-SARS-CoV-1, or authentic
virus. Group 1 and 2 antibodies did not exhibit neutralizing capacity for any of the viral strains tested.
Because both group 3 antibodies exhibited neutralizing capacity, we considered that they might block virus attachment
to ACE2, a principal mechanism of inhibition by RBD-targeted
antibodies (Hansen et al., 2020; Zost et al., 2020a). We tested
whether each antibody could block binding of soluble trimeric
S protein to recombinant human ACE2 protein. Only group 3 antibodies blocked binding to ACE2 (Figure 2H). Similar to the

pattern we observed for neutralization, COV2-2531 fully blocked
ACE2 binding, whereas C126 partially blocked binding, with less
than 50% inhibition at maximal effect (Figure 2G). Therefore, it is
likely that COV2-2531 neutralizes virus infection at least in part
by blocking binding to ACE2.
We assessed binding of all six antibodies to variants P.1
(Gamma), P.2 (Zeta), B.1.429 (Epsilon), B.1.1.7 (Alpha), B.1.135
(Beta), and B.1.1.298 (Figure S3). Antibody binding of both group
1 and 2 mAbs was largely affected by variant residues in B.1.1.7
or B.1.135. However, group 3 antibody COV-2531 maintained its
ability to bind all variants tested. C126, the less mutated counterpart of the group 3 public clonotype, exhibited a decrease in
binding to P.2, B.1.1.7, and B.1.135 (Figure 2I).
Because COV2-2531 maintained binding to all variants tested,
we tested whether it retained its neutralization capacity. Group 3
antibodies COV2-2531 and C126 were tested against clinical
isolates for B.1.1.7 (Alpha), B.1.1.298, and B.1.429 (Epsilon) viruses. The mAbs also were tested against a chimeric WA1/
2020 virus encoding the S gene of B.1.1.28 (Gamma, WashB.1.1.28). These results were compared with neutralization of
WA1/2020 and an isogenic mutant containing the D614G mutation (WA1/2020 D614G) (Figure 2J). C126 lacked inhibitory activity against authentic SARS-CoV-2 viruses. In comparison,
COV2-2531 neutralized the panel of variant SARS-CoV-2 viruses
comparably with WA1/2020, with IC50 values ranging from 85 to
522 ng/mL (Figure 2K).
Binding sites of identified clonotype antibodies
We used negative stain electron microscopy (EM) to image FabSARS-CoV-2 S6Pecto complexes. Even though all of the

Figure 2. Reactivity and functional activity of group 1, 2, and 3 antibodies
Group 1 antibodies are shown in light or dark purple, group 2 antibodies are in red or pink, and group 3 antibodies are in light or dark orange. mAb DENV 2D22 was
used as a negative control antibody, as shown in the lines in black. All experiments are performed in biological replicates and technical triplicates. Biological
replicate from representative single experiment is shown.
(A) ELISA binding to SARS-CoV-2 S6Pecto, SARS-CoV-2 RBD, or SARS-CoV-1 S2Pecto was measured by absorbance at 450 nm. Antibody concentrations
starting at 0.4 mg/mL were used and titrated 2-fold.
(B) Neutralization activity of antibodies to VSV-SARS-CoV-2, VSV-SARS-CoV-2/D614G, and VSV-SARS-CoV-1 determined by using real-time cell analysis
(RTCA) assay. The percent of neutralization is reported. Antibody concentrations started at 10 mg/mL and were titrated 3-fold.
(C) Neutralization activity of antibodies to authentic SARS-CoV-2 (USA-WA1/2020) determined by measuring dsRNA intensity per cell count after Calu3 lung
epithelial cells were inoculated with SARS-CoV-2. Antibody concentrations started at 10 mg/mL and were titrated 3-fold.
(D) Antibody binding to full-length S (gray) or S protein C-terminal S2 region (red) expressed on the surface of HEK293T cells that were fixed and permeabilized.
Antibodies were screened at 1 mg/mL. Antibody reactivity was measured by flow cytometry, and cellular florescence values were determined. COV2-2490, an
NTD-directed antibody, was used as a control.
(E) Binding to VSV-SARS-CoV-2-infected Vero cells (SARS-CoV-2 wild-type [WT]) was measured using flow cytometry, and median florescence intensity values
were determined for dose-response binding curves. Antibody was diluted 3-fold starting from 10 mg/mL.
(F) Binding to S protein C-terminal S2 region expressed on HEK293T cells (SARS-CoV-2 WT S2) was measured using flow cytometry, and mean fluorescence
intensity values were determined for dose-response binding curves. Antibody was diluted 3-fold starting from 10 mg/mL.
(G) Inhibition of ACE2 binding curves for COV2-2531 or C126. Antibody concentrations started at 10 mg/mL and were titrated 3-fold to identify ACE2 blocking
curves. COV2-2531 is shown in light orange, and C126 is shown in dark orange.
(H) The half maximal concentration (EC50) and half maximal inhibitory concentration (IC50) values for each of the assay curves in Figures 3A–3E. All values are
denoted as mg/mL. ACE2 blocking was determined by measuring amount of ACE2 with FLAG tag binding in the presence of each antibody, measured by binding
of an anti-FLAG antibody. Percent blocking is shown, calculated by using ACE2 binding without antibody as 0% blocking.
(I) Binding of each antibody to several variants of concern spike proteins. Binding of each antibody (at 1 mg/mL) to the SARS-CoV-2 spike variants is shown relative
to the antibody’s binding to the WT spike, defined as a value of 1.0. The relative amounts of each variant expressed in cells were estimated using the signal for
antibody 1A9, normalizing the average 1A9 binding (at 1 mg/mL) for each variant to the average 1A9 binding with the WT construct. For each public clonotype
antibody, the binding values to each variant spike were corrected for spike expression equivalent to that of the WT spike. Darker blue indicates less change to
binding of that antibody to the variant. Lighter blue color indicates more change for binding of that antibody to the variant.
(J) Neutralization curves of group 3 antibodies against variant SARS-CoV-2 strains. Antibodies were tested for inhibition of infection of the indicated viruses on
Vero-TMPRSS2 cell monolayer cultures using a focus reduction neutralization test.
(K) Antibody neutralization IC50 values for group 3 antibodies against variant SARS-CoV-2 strains. One representative experiment of two performed in duplicate
and mean IC50 values (ng/mL) from two independent experiments are shown.
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antibodies bound to S protein in ELISA as IgG1, only the group 3
antibody Fabs COV2-2531 and C126 formed complexes visualized on EM grids, suggesting that some antibodies may require
an IgG format for strong binding (Figure 3A; Figure S4). Low-resolution 3D reconstructions for COV2-2531 and C126 showed that
these two antibodies bind the side of the RBD and recognize the
cryptic face of the RBD that is accessible only in the ‘‘open’’ position of the RBD in the context of the S trimer (Figures 3B and 3C).
We then tested binding of antibodies to infected Vero cells that
were inoculated with VSV-SARS-CoV-2 chimeric viruses (Figure S5). Antibodies from each of the groups bound to infected
cells dose-dependently, with the group 3 RBD-reactive antibodies exhibiting greater binding than the group 1 or 2 S2-reactive antibodies (Figures 2E and 2H). Binding of the group 3
antibodies correlated with their neutralization capacity, because
COV2-2531 showed greater binding than C126. The capacity to
bind to infected cells also suggested that these antibodies could
act in vivo not only by direct virus neutralization but also through
Fc-mediated functions.
We used competition-binding ELISA for pairwise comparison
of antibodies binding to the S6Pecto protein (Figure 3D). Members of each public clonotype group clustered with the other
member of the same group by competition binding. We also
competed the antibodies for binding against a larger group of
epitope-mapped antibodies we previously described (Zost
et al., 2020b) that cover various sites on the S protein and against
rCR3022 (Yuan et al., 2020b), which bind less well to the RBD of
SARS-CoV-2 compared with SARS-CoV-1 and do not block
ACE2 binding (Figure 2G). Both group 3 antibodies competed
with rCR3022, with COV2-2531 exhibiting a higher level of
competition than C126. None of the group 1 or 2 antibodies
competed with the reference antibodies tested (Figure 3E).
We then determined the critical binding residues at the amino
acid level for each of the public clonotype antibodies by
screening for binding to alanine scanning mutant libraries of
the SARS-CoV-2 S protein. A372 and K378 were critical residues
for COV2-2531 binding. For C126, we also identified A372 and
K378, but with additional critical residues Y369, N370, F374,
and P384 (Figure 3F; Figure S6). The identified residues are
consistent with the binding site identified in the negative stain
EM analyses and overlap with the epitope of CR3022 (Yuan
et al., 2020b). It was curious that several SARS-CoV-2-specific
neutralizing antibodies competed with CR3022, which also binds
to SARS-CoV-1 but is non-neutralizing. SARS-CoV-1 has an Nglycosylation site at N370 in the binding site for these two mAbs,
which SARS-CoV-2 lacks (Yuan et al., 2020b). This difference in
glycosylation likely explains why COV2-2531 and C126 do not
bind or neutralize SARS-CoV-1, even though they recognize
the relatively conserved cryptic face of the RBD (Figure S7). In
the alanine scanning libraries, native alanine residues are
changed to serine. It is possible that A372 was identified as critical for binding by COV2-2531 and C126 because the A372S mutation results in the introduction of N-linked glycosylation of
N370, rather than making direct side-chain contact with the
antibodies.
Screening the group 1 and 2 antibodies against the SARSCoV-2 alanine scanning mutation library confirmed that they
bound to the S2 domain. For the group 1 antibodies COV2-
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2002 and COV2-2333, we identified critical residues for both antibodies (Y917, Q920, K921) in the heptad repeat (HR1) region of
S2. These residues are conserved between SARS-CoV-2 and
SARS-CoV-1. For the group 2 antibodies, screens identified
two regions of residues that were critical for binding. For both
COV2-2164 and CnC2t1p1 B10, we identified K814 (also
conserved between SARS-CoV-2 and SARS-CoV-1) as critical
for binding. In addition, for both antibodies, we also identified
R995, and for CnC2t1p1_B10, I980 and Q1002 (Figure 3F; Figure S6). K814 is not close to I980, R995, or Q1002 on the S protein structure. However, inspection of the available S protein
structures (PDB: 6XR8 and 7C2L) suggested that residues
I980, R995, and Q1002 are not readily accessible to antibodies
in the full S protein or even in the absence of S1. These residues
make interactions that likely help maintain S2 structure, and so
their mutation could indirectly affect group 2 antibody binding.
We conclude that K814 is an epitope residue for group 2 antibodies COV2-2164 and CnC2t1p1_B10. These results suggest
that the mAbs in each public clonotype group have essentially
identical critical epitope residues.
Functional properties of germline-revertant forms of
antibodies from each identified public clonotype
To determine whether the function of each antibody group was
due to germline-encoded reactivity or the result of somatic
mutations, we investigated the equivalent germline-encoded antibodies for each public clonotype. Heavy and light chain variable
region sequences of antibodies COV2-2002, COV2-2164, and
COV2-2531 were aligned with the germline sequences of
[IGHV3-7/IGHJ4/ + IGLV3-1/IGLJ3], [IGHV1-69/IGHJ4 +
IGKV3-11/IGKJ4], or [IGHV4-59/IGHJ3 + IGLV6-57/IGLJ2],
respectively. Each residue that differed from the germline gene
was reverted back to the inferred germline residue (Figure S8).
We then tested whether the germline revertants of the antibodies
in each group shared similar functional properties with their somatically mutated counterparts. Each germline-revertant antibody was tested for binding to SARS-CoV-2 S6Pecto, SARSCoV-2 RBD, or SARS-CoV-1 S2Pecto proteins. The group 1
germline revertant did not bind to SARS-CoV-2 S6Pecto or
SARS-CoV-1 S2Pecto. The group 2 germline revertant maintained binding to both SARS-CoV-2 and SARS-CoV-1 proteins
but exhibited lower binding avidity (higher EC50 values) than its
matured counterparts COV2-2164 or CnC2t1p1_B10. The group
3 germline revertant maintained binding to SARS-CoV-2 S6Pecto
and RBD proteins (Figures 4A and 4D). Each germline revertant
also bound to the surface of virus-infected cells (Figures 4B
and 4D). Although none of the germline revertants exhibited
neutralizing capacity (Figures 4C and 4D), the group 3 germline
revertant showed a low level of ACE2 blocking (Figures 4D and
4E).
COV2-2531 confers protection in vivo
MAbs can act by direct virus inactivation, but binding of some
mAbs to the surface of virus-infected cells (Figures 2E and 2H)
suggested that these antibodies also might act through Fc-mediated functions. Therefore, it was important to test some public
clonotypes in vivo. We tested the efficacy of these antibodies
against SARS-CoV-2 in vivo. We used K18-hACE2 transgenic
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Figure 3. Epitope identification and structural characterization of antibodies

(A) Negative stain EM of SARS-CoV-2 S6Pecto
protein in complex with Fab forms of different
mAbs. Negative stain 2D classes of SARS-CoV2 S protein incubated with COV2-2531 or C126.
Box size is 128 pix at 4.36 Å/pix.
B
D
(B) mAb COV2-2531 3D volume with critical residues 372 and 275 shown in red on the S protein
(blue). RBD is in the open position. Density corresponds to three fabs, as we docked a single Fab
structure onto the EM density map, shown in
magenta.
(C) MAb C126 3D volume with critical binding
residues shown in red. The Fab is docked to a
protomer of SARS-CoV-2 S protein in the open
conformation. Top left is the RBD positioned in
C
open conformation, with the other two protomers
in the trimer in closed position. The S protein is
shown in green, with the RBD in yellow. The Fab is
shown in magenta.
(D) Competition-binding ELISA results for mAbs
within each clonotype group. Unlabeled blocking
antibodies applied to antigen first are listed across
the top, while biotinylated antibodies that are
E
added to antigen-coated wells second are indicated on the left. The number in each box represents percent un-competed binding of the biotinylated antibody in the presence of the indicated
competing antibody. Heatmap colors range from
dark gray (<40% binding of the biotinylated antibody) to light gray (>80% binding of the biotinylated antibody). Experiment was performed in
biological replicate and technical triplicate. Biological replicate from representative single
experiment is shown.
(E) Competition-binding ELISA data using group 1,
2, or 3 antibodies against epitope-mapped reference antibodies. Biotinylated antibodies are indiF
cated on the left, and the unlabeled antibodies
applied to antigen first are indicated across the
top. Heatmap colors range from dark gray (<20%
binding of the biotinylated antibody) to light gray
(>50% binding of the biotinylated antibody).
Experiment was performed in biological replicate
and technical triplicates. Biological replicate from
representative single experiment shown.
(F) Alanine scanning mutagenesis results for group
1, 2, or 3 antibodies. S2 epitope residues are
shown (green spheres or blue spheres) on the S protein structure (PDB: 6XR8), S1 is colored yellow, and S2 is red. RBD epitopes are shown in red on the RBD
structure (PDB: 6XR8). Primary data are shown in Figure S5.

mice, which develop severe lung infection and disease after
intranasal inoculation (Golden et al., 2020; Winkler et al., 2020;
Zheng et al., 2021). K18-hACE2 transgenic mice received either
one antibody from group 2 (COV2-2164), one antibody from
group 3 (COV2-2531), or an isotype-control antibody (DENV
2D22) via intraperitoneal injection (200 mg, 10 mg/kg) 1 day prior
to intranasal inoculation with 103 plaque-forming units (PFUs) of
SARS-CoV-2 (WA1/2020). Mice treated with COV2-2531 were
protected completely from weight loss (Figure 5A) and showed
reduced viral infection in the lung, nasal wash, heart, and brain
(Figure 5B) compared with the isotype-control antibody-treated
group. However, mice treated with COV2-2164 were not protected from weight loss, yet showed a reduction in viral load in

the lung and brain but not in the nasal wash and heart (Figure
5B). Thus, antibodies that compete for binding with the SARSCoV-1 mAb rCR3022 can be elicited after SARS-CoV-2 infection, some of which can confer protection.
Public clonotypes shared between vaccine and
convalescent responses to SARS-CoV-2 S protein
We hypothesized that SARS-CoV-2 mRNA vaccines might induce
public clonotypes that are shared with those seen in convalescent
individuals after natural infection. We obtained peripheral blood
mononuclear cells from a volunteer 10 days after the first vaccine
dose and 7 days after second vaccine dose with the Pfizer-BioNTech vaccine. Circulating plasmablasts were enriched directly
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Figure 4. Germline-revertant antibody reactivity and functional activity
Group 1, 2, or 3 germline-revertant antibodies are shown in purple, pink, or yellow, respectively. DENV 2D22 was used as a control antibody for all assays, as
shown in the lines in black. All experiments were performed in biological replicate and technical triplicate. Biological replicate from representative single
experiment is shown, mean ± SD of triplicates is shown.
(A) Binding to SARS-CoV-2 S6Pecto, SARS-CoV-2 RBD, or SARS-CoV-1 S2Pecto was measured by absorbance at 450 nm, as shown in the first three columns.
(B) Binding to Vero cells infected with VSV-SARS-CoV-2, measured by flow cytometric analysis and reported as median florescence intensity.
(C) Results for neutralization curves for replication-competent VSV chimeric viruses in real-time cell analysis (RTCA) are shown in the next three columns,
measured by percent neutralization calculated by normalized cell index.
(D) Binding EC50 and neutralization IC50 values for each of the assay curves in Figure 5A. All values are denoted as mg/mL. ACE2 blocking was determined by
measuring the amount of ACE2 with FLAG tag binding in the presence of each antibody, measured by binding of an anti-FLAG antibody. Percent blocking is
shown, calculated by using ACE2 binding without antibody as 0% blocking.
(E) Inhibition binding curves for the group 3 germline-revertant antibody. The starting antibody concentration used was 10 mg/mL and was titrated 3-fold serially to
obtain ACE2-blocking curves.

from blood by negative selection using paramagnetic beads and
purified further by flow cytometric sorting (Figures 6A and 6B).
Sorted plasmablasts were loaded on a Beacon microfluidics instrument for single-cell secreted antibody binding screening and
antibody gene sequencing or in a Chromium single-cell microfluidics device (10X Genomics) followed by reverse transcription with
PCR and sequence analysis to obtain paired antibody sequences,
as described previously (Zost et al., 2020b). Enzyme-linked immunospot (ELISpot) assay analysis revealed a large increase in the
frequency of S-reactive cells in the enriched plasmablast cell fraction on day 7 after the second vaccination compared with that
on day 10 after the first vaccine dose, confirming induction of
target-specific responses in this individual. SARS-CoV-2
S6Pecto-specific secreted antibodies were of IgG and IgA classes
and accounted for >10% of total plasmablasts (Figure 6C).
Further, single-cell antibody secretion analysis of a total of 4,797
purified plasmablasts revealed that a large fraction of SARSCoV-2-reactive clones (including S6Pecto- and/or RBD-reactive
clones) secreted RBD-specific IgG (Figure 6D).
We also analyzed antibody reactivity and neutralization in serum
collected on the day before vaccination (day 0), on day 10 after the
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first vaccine dose, on day 7 after the second vaccine dose, and on
day 28 after the second vaccine dose. The reactivity of serum antibodies to both SARS-CoV-2 S6Pecto and SARS-CoV-2 RBD was
measured by ELISA for binding (Figure 6F) and by VSV-SARSCoV-2 neutralizing assay (Figure 6G). Binding and neutralizing activities steadily increased over time, with maximal activity detected on day 28 after the second vaccine dose.
We obtained 725 paired heavy and light chain sequences from
plasmablasts following primary immunization and 8,298 paired
sequences from plasmablasts following the second dose of vaccine. The same procedure was carried out on a sample collected
35 days after onset of symptoms from a convalescent individual
with confirmed SARS-CoV-2 infection. This individual’s serum
had been determined previously to contain neutralizing antibodies (Zost et al., 2020b). Single-cell antibody secretion analysis revealed that a minor fraction (0.5%) of total plasmablasts
produced S-protein-reactive antibodies. We identified 1,883
paired heavy and light chain antibody sequences from this
specimen.
Antibody sequences identified in these new studies and sequences we collected from previous SARS-CoV-2 antibody
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antibodies specific to the SARS-CoV-2 S protein. Within that
panel of mAbs, 8 of 26 clonotypes reacted with SARS-CoV-2
RBD protein, and 6 of the 26 public clonotypes cross-reacted
with both SARS-CoV-1 and SARS-CoV-2 (Figure 7). Most antibodies shared in public clonotypes were IgG, with a subset of
IgA noted. This finding shows that the Pfizer-BioNTech vaccine
induces many antibodies that are genetically similar to ones elicited through natural SARS-CoV-2 infection, including multiple
public clonotypes in convalescent donors encoded by
commonly used VH genes, such as IGHV3-53, IGHV3-66,
IGHV1-58, IGHV3-30, and IGHV3-30-3. Additionally, of the 37 total public clonotypes, 16 bound to RBD, and of these, 11 of 16
were neutralizing. All neutralizing public clonotypes recognized
RBD. However, of the 37 public clonotypes identified, 21 are
directed to antigenic sites other than the RBD, including ones
described here directed to the S2 domain. Overall, these results
suggest that many of the public clonotypes observed in previously infected individuals likely are found in vaccinated
individuals.
DISCUSSION

Figure 5. Antibody-mediated protection against SARS-CoV-2 challenge in mice
(A and B) Eight-week-old male K18-hACE2 transgenic mice were inoculated
by the intranasal route with 103 PFUs of SARS-CoV-2 (WA1/2020 strain). One
day prior to infection, mice were given a single 200-mg dose of COV2-2351 or
COV2-2164 by intraperitoneal injection. (A) Weight change. Statistical analysis
was performed only between isotype- and COV2-2351-treated groups. For
isotype and COV2-2531 (mean ± SEM; n = 8–10, two experiments: unpaired t
test of area under the curve; ****p < 0.0001). For COV2-2164 (mean ± SEM; n =
8, two experiments). (B) Viral RNA levels at 7 days post-infection in the lung,
nasal wash, heart, and brain as determined by qRT-PCR. For isotype and
COV2-2531 (mean ± SEM; n = 8–10, two experiments: one-way ANOVA with
Turkey’s post-test: not significant [ns], *p < 0.05, ***p < 0.001, ****p < 0.0001,
comparison with the isotype control mAb-treated group). For COV2-2164
(mean ± SEM; n = 8, two experiments).

discovery studies were clustered as described in Figure 1. We
identified a total of 37 public clonotypes, 26 of which represented clonotypes shared between antibodies isolated from
the vaccinee and individuals with exposure history to natural
SARS-CoV-2 infection (Figure 6H). The antigen-binding specificity of each group was inferred through review of data in each
respective publication in which the antibodies were reported.
Fourteen of the 26 newly identified shared clonotypes encoded

The high number of identified public B cell clonotypes in the
response to SARS-CoV-2 infection or vaccination is striking.
Many public clonotypes are shared between both infected and
vaccinated individuals. Public clonotypes were induced by
each of the currently known antigenic sites on the S protein
and are found in both the neutralizing and non-neutralizing repertoires. Some clonotypes in the shared SARS-CoV-2 response
appear preconfigured in the germline state to recognize particular S epitopes, and this recognition likely is driven by particular
structural features on S. In this study, we compared the sequences of more than 14,000 paired B cell sequences encoding
antibodies to S protein of SARS-CoV-2. Likely, the availability of
large numbers of paired antibody gene sequences from a multitude of donors contributed to our ability to identify such a high
number of paired-sequence public clonotypes.
Several neutralizing public clonotypes have been identified
previously, most commonly clonotypes encoded by the closely
related heavy chain genes IGHV3-53, IGHV3-66 (Tan et al.,
2021; Yuan et al., 2020a), IGHV1-2 (Rapp et al., 2021), and
IGHV3-30 (Robbiani et al., 2020). Structural features of these
public clonotypes likely drive the frequent selection of such
clones, such as the canonical configuration of aromatic residues
in the public clonotype IGHV1-58 + IGHJ3 and IGKV3-20 +
IGKJ1 that engages the SARS-CoV-2 RBD F486 residue (Dong
et al., 2021). Members of this public clonotype, such as COV22196, engage the RBD using predominantly germline-encoded
residues in both the heavy and light chain (Dong et al., 2021;
Kreer et al., 2020; Nielsen et al., 2020; Robbiani et al., 2020;
Tortorici et al., 2020). Identification of public clonotypes from
multiple donors suggests these antibodies could contribute to
humoral responses that mediate protection if they appear not
only in memory B cells but also as antibodies from plasma cells
secreted into the serum (Voss et al., 2020). The high prevalence
of public clonotypes elicited to the SARS-CoV-2 S trimer may
contribute to the high efficacy of S-encoding mRNA vaccines
in large populations.
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If diverse individuals independently make the same antibody in
response to an antigen, there could be a constant and collective
selective pressure on that epitope, resulting in a high potential for
escape variants at that site. For example, although IGHV3-53and IGHV3-66-encoded public clonotypes have been described
in numerous individuals, neutralization of these antibodies is
impacted adversely by the K417N or K417T substitutions present in the B.1.351 or P.1 SARS-CoV-2 variants of concern,
respectively (Yuan et al., 2021). A similar case was described
for IGHV1-2-encoded antibodies that target the RBD and
IGHV1-24-encoded antibodies that target the NTD. These antibodies are found in the serum of convalescent individuals
(Voss et al., 2020), but neutralization of these antibodies is negatively affected for 501Y.V2 variant viruses (Wibmer et al., 2021). A
possible explanation for the selective pressure that led to the
emergence and propagation of these variants is the humoral immunity mediated by these public clonotypes.
The new group 3 public clonotype neutralizing and protective
antibodies described here bind to the cryptic face of the RBD
and compete with the SARS-CoV-2 non-neutralizing mAb
CR3022. Neutralizing antibodies that bind to the more conserved
base of the RBD are of interest, because these sites are largely
unaffected by common mutations in the variants of concern,
such as E484K, K417N, and N501Y (Yuan et al., 2021). Importantly, recent work has identified a B.1.1.7 variant with a deletion
of RBD residues 375–377. This deletion disrupts the epitope of
CR3022, yet appears to be functionally tolerated (Rennick
et al., 2021). Because group 3 antibodies share a similar epitope,
with critical residues of COV2-2531 and C126 being K378 and
A372, but with additional critical residues of Y369, N370, F374,
and P384 identified for C126, this deletion might abrogate binding of antibodies from this public clonotype. Group 3 antibody
characterization reveals additional insights on antibodies binding to epitopes similar to that of CR3022. Recently published
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literature suggests that there is an avidity threshold that affects
antibody neutralization at the cryptic face of the RBD (Wu
et al., 2020). We hypothesize that affinity improvements via somatic hypermutation play an important role in the ability of
COV2-2531 to neutralize, particularly because neither C126
nor the germline revertant of group 3 neutralizes virus.
To our knowledge, public clonotypes specific to the S2
domain have not been described. In this study, we identified
two public clonotypes that target the S2 domain of the S trimer.
These mAbs do not neutralize, but they react with S proteins of
both SARS-CoV-2 and SARS-CoV-1. It is likely that these S2 epitopes are the target of non-neutralizing antibodies in multiple individuals following infection or vaccination. Previous studies
have identified broadly immunogenic epitopes that are
conserved in the functional domains of the SARS-CoV-2 S trimer
S2 domain, including cross-reactivity to endemic coronaviruses,
and therefore these findings have important implications for antibody and vaccine design (Ladner et al., 2021). The S2 region of
the S trimer may be more capable of recruiting preexisting memory B cells for diverse coronaviruses, because the S2 domain is
more conserved for functionally important sites such as the heptad repeat regions and fusion loop (Anderson et al., 2021).
We propose that there are essentially four classes of public
clonotypes: (1) neutralizing public clonotypes that bind to relatively invariant sites on S, (2) neutralizing public clonotypes that
bind to sites that tolerate high sequence variability, (3) nonneutralizing public clonotypes that target relatively invariant
sites, and (4) non-neutralizing public antibodies that target variable sites. The first class of antibodies is likely the most protective class in a population, because these mAbs neutralize and
recognize residues unlikely to be sustained with mutations
because of loss of viral fitness. An example of this class would
be IGHV1-58-encoded antibodies as described previously
(Dong et al., 2021). Many public clones currently identified for

Figure 6. Analysis of vaccinated donor antibody response
(A and B) Flow cytometric plots showing gating strategy to identify plasmablasts in total PBMC sample collected on day 7 after second vaccine dose (top panel) or
identification of plasmablasts after direct enrichment from whole blood at the same time point using negative selection with paramagnetic beads (bottom panel).
Blue arrow indicates enriched plasmablasts that were used for ELISpot analysis as in (B), and red arrow indicates plasmablasts (DAPI CD19loCD27hiCD38hi) that
were FACS sorted for single-cell secretion and paired antibody sequencing studies.
(C) ELISpot analysis of SARS-CoV-2 S6Pecto-specific antibody secretion using enriched plasmablasts from blood collected on day 10 after the first vaccine dose
(IgG) and day 7 after the second vaccine dose (IgG and IgA). A/Darwin/42/2020 H1N1 influenza virus hemagglutinin (HA) was used as a control for specificity of the
plasmablast response. Wells with spots (left) and number of SARS-CoV-2 S6Pecto-specific responses detected (right) are shown. Dotted line indicates values
below limit of the detection (LOD = 10 spots per 104 cells), which were set up to 5 spots per 104 cells.
(D) Pie chart representation showing frequency of RBD and SARS-COV-2 S6Pecto reactive (red), SARS-COV-2 S6Pecto reactive only (green), or RBD reactive only
(blue) plasmablasts identified as in (C). Fraction of cells that did not react to either SARS-COV-2 RBD or S6Pecto is shown in gray.
(E) Flow-cytometry-sorted plasmablasts were loaded on a Beacon instrument and assessed for binding to S6Pecto or RBD-coated beads using single-cell
antibody secretion analysis. Bright-field images of the Beacon instrument chip with individual plasmablasts loaded into the pens of the chip are shown for the
selected fields of view for each screening condition (top). False-color fluorescent images from the same fields of view (bottom) showing binding of the detection
anti-human Alexa Fluor 568-labeled antibody to the S6Pecto or RBD-coated beads that captured human antibodies secreted by single plasmablasts (visualized as
a plume from the beads that loaded into the channel of the chip). Arrow indicates cells secreting antigen-reactive IgG antibodies.
(F) ELISA binding to SARS-CoV-2 S6Pecto of serum from patient 5 at day 0 of first vaccination, day 10 after first vaccination, or day 7 after second vaccination were
measured by absorbance at 450 nm. Serum was diluted 1:75 and then diluted serially 3-fold. Experiment was performed in biological replicate and technical
triplicate. Biological replicate from representative single experiment is shown, mean ± SD of triplicates is shown.
(G) Neutralization curves of serum from patient 5 at day 0 of first vaccination, day 10 after first vaccination, or day 7 after second vaccination. A World Health
Organization (WHO) International standard for anti-SARS-CoV-2 human immunoglobulin was used as the positive control. Serum was diluted starting at a 1:25
dilution, then diluted serially 2-fold. Experiment was performed in technical triplicate.
(H) Circos plot indicating public clonotypes identified in this paper. The more opaque ribbons within the circle represent public clonotypes that are shared
between the vaccinated donor and convalescent donors after natural infection. Translucent ribbons indicate public clonotypes shared between convalescent
infection individuals. The individuals from whom sequences were derived are indicated on the inner circle. The published sources from which the sequences were
obtained are shown on the second circle. The outside circle indicates whether the individuals were naturally infected or vaccinated.
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Figure 7. Identification of public clonotypes shared between naturally infected individuals and a vaccinated donor
Table showing all public clonotypes identified. Gene usage for each clone or CDRH3 length is shown in columns 2 or 3. Reactivity profiles obtained from published
sources are shown for comparative purposes. Blue indicates positive reactivity, while white indicates that binding reactivity or neutralization was not detected.
Gray indicates reactivity profile was not found in either publication and therefore is unknown. Isotypes of antibodies in each group are listed in the eighth column. If
the group contained sequences from both vaccinated and infected individuals, it was denoted in yellow. White was used for clonotypes that were shared only
between convalescent individuals following natural infection.
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SARS-CoV-2 are categorized in the second class. While these
clones initially offer protection, this property could be lost as
widespread selective pressure on the virus is exerted on a region
with genetic and structural plasticity. Examples of this group
were discussed here, such as IGHV3-53- and IGHV3-66-encoded antibodies that target the RBD (Yuan et al., 2021). Here,
we described three new public clonotypes following natural
infection (groups 1, 2, and 3) and a total of 29 new clonotypes after mRNA vaccination. Public clonotype groups 1 and 2 fall into
the third class of antibodies described here (non-neutralizing antibodies that target invariant sites), and public clonotype group 3
antibodies fall into the second class (neutralizing public clonotypes that bind to variable sites). Future public clonotypes to
SARS-CoV-2 could be binned with this four-quadrant scheme
to better understand how public clonotypes contribute to humoral immunity against COVID-19.
Understanding the antibody response that is shared between
convalescent and vaccinated individuals also will be of
continued interest as the percentage of vaccinated individuals
increases in the face of the emergence of new viral variants of
concern. The understanding of viral epitopes that induce protective antibodies in multiple individuals has implications for predicting the most common responses to new vaccines in large
populations. The emergence of SARS-CoV-2 variants with acquired mutations in epitopes for neutralizing antibodies,
including antibody regimens currently authorized for EUA, is a
cause for concern (Collier et al., 2021; Tegally et al., 2020;
Wang et al., 2021a, 2021b). Our analyses of public clonotypes after natural infection and vaccination and their shared epitope targets may predict sites of future major antigenic changes in the S
trimer.
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Computational pipeline for the clustering
analysis

This paper

Zenodo; DOI 10.5281/zenodo.5150784

Script to create heatmaps

This paper

Zenodo; DOI 10.5281/zenodo.5150784

PyIR script used to determine sequence
characteristics of each antibody

This paper

Zenodo; DOI 10.5281/zenodo.5150784

GraphPad Prism

GraphPad

v 9.0.0

iQue Forecyt Software

Sartorius

N/A

Nanozoomer Digital Pathology

Hamamatsu

v2
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xCELLigence RTCA MP analyzer

Acea Biosciences, Inc.

N/A

xCELLigence E-Plate 96 PET cell culture
plates

Acea Biosciences, Inc.

Cat# 300601010

ÄKTA pure chromatography system

GE Healthcare Life Sciences

N/A

Biostack microplate stacker

BioTek

N/A

FEI TF20 electron microscope with Gatan
US4000 4k 3 4k CCD camera

Thermo Fisher Scientific

N/A

StrepTrap HP column

GE Healthcare Life Sciences

Cat# 28-9075-48

400 mesh copper EM grids

Electron Microscopy Services

Cat# 22451

EL406 washer dispenser

BioTek

N/A

HisTrap Excel column

GE Healthcare Life Sciences

Cat# 17-3712-06

HiTrap MabSelect SuRe 5 mL column

GE Healthcare Life Sciences

Cat# 29-0491-04

Intellicyt iQue Screener Plus

Sartorius

N/A

ImmunoSpot S6 Plate Imager

Cellular Technology Limited

N/A

RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, James. E.
Crowe, Jr. (james.crowe@vumc.org)
Materials availability
Materials described in this paper are available for distribution for nonprofit use using templated documents from Association of University Technology Managers ‘‘Toolkit MTAs,’’ available at: https://autm.net/surveys-and-tools/agreements/material-transferagreements/mta-toolkit.
Data and code availability
Sequence Read Archive deposition for the public clonotypes identified is deposited at the NCBI: PRJNA511481. Deposition for the
paired heavy and light chain plasmablast sequences, that were identified as public clonotypes, following mRNA vaccination is
deposited in GenBank with accession numbers MZ555491 through MZ555628. The sequences of COV2-2164 are deposited in GenBank with accession numbers MZ555629 and MZ555630. All other data are available in the main text or the supplementary materials.
The computational pipeline for the clustering analysis, the script to create heatmaps, and the PyIR script used to determine sequence
characteristics of each antibody are available as listed in the Key resources table. Any additional information required to reanalyze the
data reported in this paper is available from the lead contact upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Research participants
We studied three patients (patient 2 [52-year-old female], 3 [56-year-old male] and 4 [56-year-old female]) in North America with
laboratory-confirmed symptomatic SARS-CoV-2 infections that we have described previously (Zost et al., 2020b). We studied
one patient (59-year-old male) who received Pfizer-BioNTech vaccine. The studies were approved by the Institutional Review Board
of Vanderbilt University Medical Center.
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Cell lines
Vero E6 (ATCC, CRL-1586) cells were maintained at 37 C in 5% CO2 in Dulbecco’s minimal essential medium (DMEM) containing
10% heat inactivated fetal bovine serum (FBS), 10 mM HEPES pH 73, 1 mM sodium pyruvate, 1 3 non-essential amino acids,
and 100 U/mL of penicillin-streptomycin. ExpiCHO cells (Thermo Fisher Scientific, A29127) were maintained at 37 C in 8% CO2 in
ExpiCHO Expression Medium (Thermo Fisher Scientific, A2910002). Mycoplasma testing of cell lines was performed on monthly basis using a PCR-based mycoplasma detection kit (ATCC, 30-1012K), with negative results at each testing. Calu-3 (ATCC, HTB-55)
cells were maintained at 37 C in 5% CO2 in DMEM with high glucose and L-glutamine (GIBCO 11965092), containing 10% heat inactivated fetal bovine serum (FBS), and 100 U/mL of penicillin-streptomycin. Vero-TMPRSS2 cells (Zang et al., 2020) were cultured at
37 C in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES pH 7.3, 1 mM
sodium pyruvate, 1 3 non-essential amino acids, 100 U/mL of penicillin–streptomycin, and 5 mg/mL of blasticidin.
Viruses
The generation of a replication-competent VSV expressing SARS-CoV-2 S protein with a 21 amino acid C-terminal deletion that replaces the VSV G protein (VSV-SARS-CoV-2) was described previously (Case et al., 2020b). The S protein-expressing VSV virus
was propagated in MA104 cell culture monolayers (African green monkey, ATCC CRL-2378.1) (Case et al., 2020b). Viral stocks were
titrated on Vero E6 cell monolayer cultures by visualizing VSV plaques using neutral red staining. VSV-SARS-CoV-2/D614G was introduced by site directed mutagenesis. The 2019n-CoV/USA_WA1/2019 isolate of SARS-CoV-2 was obtained from the US Centers for
Disease Control (CDC). Infectious stocks were propagated by inoculating Vero CCL81 cells. Supernatant was aliquoted and stored
at 80 C. The University of Arizona group obtained the USA-WA1/2020 isolate of SARS-CoV-2 from WRCEVA. Early passage virus
stock was generated by a single passage on Vero CCL81 for 48 h. Infected cell lysate and culture supernatant was combined, subjected
to one freeze-thaw, and then centrifuged to pellet cell debris. The stock was titered to 3 x106 PFU/mL by standard plaque assay on
Vero CCL81 cells. Nanopore sequencing of these early passages confirmed the genome sequence was identical to the GenBank WA1/
2020 sequence (MN985325.1), with no mutations in the spike furin cleavage site. All work with infectious SARS-CoV-2 was performed in
Institutional Biosafety Committee-approved BSL3 or A-BSL3 facilities at Washington University School of Medicine or University of Arizona, using appropriate positive pressure air respirators and protective equipment. The WA1/2020 recombinant strains with substitutions (D614G or N501Y/D614G) or a chimeric spike gene (B.1.1.28) were obtained from an infectious cDNA clone of the 2019n-CoV/
USA_WA1/2020 strain, as previously described (Plante et al., 2021). The B.1.1.7, B.1.429, and B.1.1.298 isolates were obtained
from nasopharyngeal swabs, and all viruses were passaged once in Vero-TMPRSS2 cells and subjected to next-generation sequencing
as previously described (Chen et al., 2021) to confirm the introduction and stability of substitutions. Substitutions for each variant were
as follows: B.1.1.7: deletion of 69 and 70 and 144 and 145, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H; B.1.1.28: L18F,
T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, and T1027I; B.1.429: S13I, W152C, L452R, and D614G; B.1.1.298:
deletion of 69 and 70, Y453F, D614G, I692V, and M1229I. All virus experiments were performed in an approved biosafety level 3 facility.
METHOD DETAILS
Clustering for identification of public clonotypes
Publicly available paired sequence sets of antibody genes were obtained (Brouwer et al., 2020; Kreer et al., 2020; Liu et al., 2020;
Rogers et al., 2020; Seydoux et al., 2020; Wec et al., 2020; Zost et al., 2020b). Together with sequences derived from this paper,
public clonotypes were determined by genetic similarities of antibody sequences using the following clustering scheme. The sequences were first binned by the same heavy chain V and J genes. Following sequences then were clustered according to 70%
sequence similarity on their CDRH3 nucleotide sequence. Lastly, sequences then were binned together again if they used the
same light chain V and J genes. Clusters of sequences containing sequences from two or more donors were determined to be public
clonotypes. This clustering allowed us to identify a total of 11 public clonotypes, three of which had not been previously described.
Below are the number of sequences we derived from each publication.

Publication

Number of sequences identified

Liu et al., 2020, Nature

19

Kreer et al., 2020, Cell

18

Number of public clonotypes that are
SARS-CoV-reactive

Robbiani et al., 2020, Nature

533

2

Rogers et al., 2020 Science

33

1

Seydoux et al., 2020, Immunity

32

Brouwer et al., 2020, Science

84

Hansen et al., 2020, Science

8

Wec et al., 2020, Science

54

Zost et al., 2020b, Nature Medicine

389
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Heatmap generation
All sequences that were identified to be public clonotypes were analyzed with PyIR (Soto et al., 2020) to identify the V and J genes.
The number of sequences with corresponding V and J genes on the heavy and light chains were counted. These frequency counts
then were plotted onto the heatmap using Python Seaborn Library.
Antibody production and purification
Sequences of mAbs were synthesized using a rapid high-throughput cDNA synthesis platform (Twist Bioscience) and subsequently
cloned into an IgG1 monocistronic expression vector (designated as pTwist-mCis_G1) for mAb secretion from mammalian cell culture. This vector contains an enhanced 2A sequence and GSG linker that allows simultaneous expression of mAb heavy- and lightchain genes from a single construct upon transfection (Chng et al., 2015). We performed transfections of ExpiCHO cell cultures using
the GIBCO ExpiCHO Expression System and protocol for 50mL mini bioreactor tubes (Corning) as described by the vendor. Culture
supernatants were purified using HiTrap MabSelect SuRe (Cytiva, formerly GE Healthcare Life Sciences) on a 24-column parallel protein chromatography system (Protein Biosolutions). Purified monoclonal antibodies were buffer exchanged into PBS, concentrated
using Amicon Ultra-4 50-kDa centrifugal filter units (Millipore Sigma) and stored at 4 c until use.
Expression and purification of recombinant receptor binding domain (RBD) of SARS-CoV-2 S protein
For electron microscopy imaging of S protein in complex with Fab forms of human mAbs, we expressed a variant of S6Pecto protein
containing a C-terminal Twin-Strep-tag, similar to that described previously (Zost et al., 2020b). Expressed protein was incubated
with BioLock (IBA Lifesciences) and then isolated by Strep-tag affinity chromatography on StrepTrap HP columns (GE Healthcare),
followed by size-exclusion chromatography on TSKgel G4000SWXL (TOSOH) if needed.
ELISA binding assays
Wells of 384-well microtiter plates were coated with purified recombinant SARS-CoV-2 S6Pecto, SARS-CoV-2 RBD, or SARS-CoV
S2Pecto at 4 C overnight. Plates were blocked with 2% non-fat dry milk and 2% normal goat serum in DPBS containing 0.05%
Tween-20 for 1 h. All antibodies were diluted to a concentration of either 0.4 mg/mL for the matured antibodies or 5 mg/mL for the
germline-revertant antibodies. Antibodies were diluted in two-fold dilutions until binding was no longer detected. Bound antibodies
were detected using goat anti-human IgG conjugated with horseradish peroxidase and TMB substrate. The reaction was quenched
with 1N hydrochloric acid once color was developed. The absorbance was measured at 450 nm using a spectrophotometer (Biotek).
Cell-surface antigen-display assay
Vero cell monolayers were monitored until 80% confluent and then inoculated with VSV-SARS-CoV-2 V (WA1/2020 strain) at an MOI
of 0.5 in culture medium (DMEM with 2% FBS). For a T-225 flask, 10 mL of diluted VSV-SARS-CoV-2 virus was added to the monolayer, then incubated for 40 min. During the incubation, the flask was gently rocked back and forth every 10 min to ensure even infection. Following, the incubation the flask volume was topped off to 30 mL with 2% FBS containing DMEM and incubated for 14 h. Cells
were monitored for CPE under a microscope, were trypsinized and washed in fluorescence activated cell sorting (FACS) buffer.
100,000 infected cells were seeded per well to stain with respective antibodies. All antibody was diluted to 10 mg/mL in FACS buffer,
and then serially diluted 3-fold 7 times to stain for antibodies that react to cell-surface-displayed S protein. Infected cells then were
resuspended in 50 mL of diluted antibody. Antibody binding was detected with anti-IgG Alexa Fluor-647-labeled secondary antibodies. Cells were analyzed on an iQue cytometer for staining first by gating to identify infected cells as indicated by GFP-positive
cells, and then gated for secondary antibody binding.
Real-time cell analysis (RTCA) neutralization assay
To determine neutralizing activity of purified antibodies or human serum, we used real-time cell analysis (RTCA) assay on an xCELLigence RTCA MP Analyzer (ACEA Biosciences Inc.) that measures virus-induced cytopathic effect (CPE) (Gilchuk et al., 2020; Suryadevara et al., 2021; Zost et al., 2020b). Briefly, 50 mL of cell culture medium (DMEM supplemented with 2% FBS) was added to each
well of a 96-well E-plate to obtain background reading. A suspension of 18,000 Vero cells in 50 mL of cell culture medium was seeded
in each well, and the plate was placed on the analyzer. Measurements were taken automatically every 15 min, and the sensograms
were visualized using RTCA software version 2.1.0 (ACEA Biosciences Inc). SARS-CoV-2 S VSV, SARS-CoV-2 S D614G VSV, or
SARS-CoV-1 (0.02 MOI, 120 PFU per well) was mixed 1:1 with a respective dilution of mAb or heat-inactivated human serum
in a total volume of 100 mL using DMEM supplemented with 2% FBS as a diluent and incubated for 1 h at 37 C in 5% CO2. At
16 h after seeding the cells, the virus-mAb mixtures were added in replicates to the cells in 96-well E-plates. Triplicate wells containing virus only (maximal CPE in the absence of mAb) and wells containing only Vero cells in medium (no-CPE wells) were included as
controls. Plates were measured continuously (every 15 min) for 48 h to assess virus neutralization. Normalized cellular index (CI)
values at the endpoint (48 h after incubation with the virus) were determined using the RTCA software version 2.1.0 (ACEA Biosciences Inc.). Results are expressed as percent neutralization in a presence of respective mAb relative to control wells with no CPE
minus CI values from control wells with maximum CPE. RTCA IC50 values were determined by nonlinear regression analysis using
Prism software.
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Competition-binding ELISA
Wells of 384-well microtiter plates were coated with purified recombinant SARS-CoV-2 S6Pecto protein at 4 C overnight. Plates were
blocked with 2% bovine serum albumin (BSA) in DPBS containing 0.05% Tween-20 for 1 h. Each antibody was diluted to a concentration of 10 mg/mL. Next, biotinylated antibodies were diluted to 2.5 mg/mL and added to the primary antibody solution without
washing the plate to a final concentration of 0.5mg/mL. Biotinylated antibody binding was detected with horseradish peroxidase-conjugated avidin (Sigma) and developed with TMB. The reaction was quenched with 1N hydrochloric acid once color was developed.
Absorbance was measured at 450 nm using a spectrophotometer.
ACE2 blocking assay
Wells of 384-well microtiter plates were coated with purified recombinant SARS-CoV-2 S6Pecto protein at 4 C overnight. Plates were
blocked with 2% nonfat dry milk in DPBS containing 0.05% Tween-20 for 1 h. Each antibody was diluted to a concentration of 10 mg/
mL. Next, recombinant human ACE2 protein with a C-terminal FLAG tag was diluted to 2 mg/mL and added to the antibody solution
without washing the plate to a final concentration of ACE2 of 0.4 mg/mL. ACE2 binding was detected using HRP-conjugated antiFLAG antibodies and developed with TMB substrate. The reaction was quenched with 1 N hydrochloric acid once color was developed. Absorbance was measured at 450 nm using a spectrophotometer.
dsRNA staining neutralization assay
Calu-3 cells were seeded at 5,000 cells per well in SCREENSTAR 384-well black plates (Greiner) and allowed to adhere overnight.
The cells then were treated with antibodies in 12 concentrations spanning from 5.65 3 10 5 mg/mL to 10 mg/mL and immediately
transferred to a BSL-3 facility where they were inoculated with SARS-CoV-2 at an approximate MOI of 1 PFU/cell in 50 mL medium,
and incubated for 48 h. At the end of the incubation, plates were submerged in PBS with 4% paraformaldehyde and 4% sucrose
solution for 30 minutes to fix. Cells then were permeabilized with 0.2% Triton X-100/PBS for 10 min and blocked with 5% BSA/
PBS for 1 h. Primary J2 anti-dsRNA (Scicons #10010500) antibody solution at a 1:1,000 dilution was placed on the cells overnight
at 4 C. Cells were washed with 0.1% Tween-20/PBS (PBST) three times and plates were incubated with secondary goat anti-mouse
Alexa Fluor-546-labeled antibody at 1:1,000 dilution (Thermo Fisher Scientific) for 2 h at room temperature in the dark. Plates were
washed three times with PBST and incubated with DAPI for 30 min at room temperature in the dark. Plates were then imaged with
fluorescent microscopy on a Nikon Eclipse TI2 automated microscopy system with a 20 3 objective. Six frames per well were imaged
and sum dsRNA fluorescence intensity, normalized to cell count by DAPI, was measured by Nikon Elements imaging software.
Focus reduction neutralization test
Serial dilutions of mAbs (starting at 10 mg/mL dilution) were incubated with 100 FFU of different SARS-CoV-2 strains for 1 h at 37 C.
Antibody–virus complexes were added to Vero-TMPRSS2 cell monolayers in 96-well plates and incubated at 37 C for 1 h. Subsequently, cells were overlaid with 1% (w/v) methylcellulose in MEM. Plates were collected 30 h later by removing overlays and fixed
with 4% PFA in PBS for 20 min at room temperature. Plates were washed and sequentially incubated with an oligoclonal pool of
SARS2-2, SARS2-11, SARS2-16, SARS2-31, SARS2-38, SARS2-57 and SARS2-71 (Case et al., 2020a) anti-S antibodies and
HRP-conjugated goat anti-mouse IgG (Sigma, 12-349) in PBS supplemented with 0.1% saponin and 0.1% bovine serum albumin.
SARS-CoV-2-infected cell foci were visualized using TrueBlue peroxidase substrate (KPL) and quantitated on an ImmunoSpot microanalyzer (Cellular Technologies).
Mouse experiments
Animal studies were carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health. The protocols were approved by the Institutional Animal Care and Use Committee at the Washington
University School of Medicine (assurance number A3381–01). Virus inoculations were performed under anesthesia that was induced
and maintained with ketamine hydrochloride and xylazine, and all efforts were made to minimize animal suffering. Heterozygous K18hACE c57BL/6J mice (strain: 2B6.Cg-Tg(K18-ACE2)2Prlmn/J) were obtained from The Jackson Laboratory. Animals were housed in
groups and fed standard chow diets. One day prior to infection, mice were given a single 200 mg dose of COV2-2351 or COV2-2164
by intraperitoneal injection. Eight- to nine-week-old mice were administered 103 PFU of SARS-CoV-2 by intranasal administration.
Measurement of viral burden in mouse tissues
Tissues were weighed and homogenized with zirconia beads in a MagNA Lyser instrument (Roche Life Science) in 1,000 mL of DMEM
medium supplemented with 2% heat-inactivated FBS. Tissue homogenates were clarified by centrifugation at 10,000 rpm for 5 min
and stored at 80 C. RNA was extracted using the MagMax mirVana Total RNA isolation kit (Thermo Fisher Scientific) on the Kingfisher Flex extraction robot (Thermo Fisher Scientific). RNA was reverse transcribed and amplified using the TaqMan RNA-to-CT 1Step Kit (Thermo Fisher). Reverse transcription was carried out at 48 C for 15 min followed by 2 min at 95 C. Amplification was
accomplished over 50 cycles as follows: 95 C for 15 s and 60 C for 1 min. The number of copies of SARS-CoV-2 N gene RNA in
samples was determined using a previously published assay (Case et al., 2020a). Briefly, a TaqMan assay was designed to target
a highly conserved region of the N gene (forward primer: ATGCTGCAATCGTGCTACAA; Reverse primer:m
GACTGCCGCCTCTGCTC; Probe: /56-FAM/TCAAGGAAC/ZEN/AACATTGCCAA/3IABkFQ/). This region was included in an RNA
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standard to allow for copy number determination down to 10 copies per reaction. The reaction mixture contained final concentrations
of primers or probe of 500 or 100 nM, respectively.
Electron microscopy sample and grid preparation, imaging and processing of S6Pecto–Fab complexes
Fabs were produced by digesting recombinant chromatography-purified IgGs using resin-immobilized cysteine protease enzyme
(FabALACTICA, Genovis). The digestion occurred in 100 mM sodium phosphate and 150 mM NaCl pH 7.2 (PBS) for around 16 h
at ambient temperature. To remove cleaved Fc from intact IgG, the digestion mix was incubated with CaptureSelect Fc resin (Genovis) for 30 min at ambient temperature in PBS buffer.
For screening and imaging of negatively-stained SARS-CoV-2 S6Pecto protein in complex with human Fabs, the proteins were
incubated at a Fab:S molar ratio of 4:1 for about 1 h at ambient temperature or overnight at 4 C. Approximately 3 mL of the sample
at concentrations of about 10 to 15 mg/mL was applied to a glow-discharged grid with continuous carbon film on 400 square mesh
copper electron microscopy grids (Electron Microscopy Sciences). The grids were stained with 0.75% uranyl formate (Ohi et al.,
2004). Images were recorded on a Gatan US4000 4k 3 4k CCD camera using an FEI TF20 (TFS) transmission electron microscope
operated at 200 keV and control with Serial EM. All images were taken at 50,000 3 magnification with a pixel size of 2.18 Å per pixel in
low-dose mode at a defocus of 1.5 to 1.8 mm. The total dose for the micrographs was around 30 e per Å2. Image processing was
performed using the cryoSPARC software package. Images were imported, CTF-estimated, and particles were picked. The particles
were extracted with a box size of 256 pixels and binned to 128 pixels (pixel size of 4.36 Å/pix) and 2D class averages were performed.
Epitope mapping of antibodies by alanine scanning
Epitope mapping was performed essentially as described previously (Davidson and Doranz, 2014) using SARS-CoV-2 (Wuhan-Hu-1
strain) S protein RBD and S2 shotgun mutagenesis mutation libraries, made using a full-length expression construct for S protein. 184
residues of the RBD (between S residues 335 and 526), and 513 S2 residues (between residues 689 1247) were mutated individually
to alanine, and alanine residues to serine. Mutations were confirmed by DNA sequencing, and clones arrayed in a 384-well plate, one
mutant per well. Binding of mAbs to each mutant clone in the alanine scanning library was determined, in duplicate, by highthroughput flow cytometry. A plasmid encoding cDNA for each S protein mutant was transfected into HEK293T cells and allowed
to express for 22 h. Cells were fixed in 4% (v/v) paraformaldehyde (Electron Microscopy Sciences), and permeabilized with 0.1%
(w/v) saponin (Sigma-Aldrich) in PBS plus calcium and magnesium (PBS++) before incubation with mAbs diluted in PBS++, 10%
normal goat serum (Sigma), and 0.1% saponin. mAb screening concentrations were determined using an independent immunofluorescence titration curve against cells expressing wild-type S protein to ensure that signals were within the linear range of detection.
Antibodies were detected using 3.75 mg/mL of Alexa Fluor-488-labeled secondary antibodies (Jackson ImmunoResearch Laboratories) in 10% normal goat serum with 0.1% saponin. Cells were washed three times with PBS++/0.1% saponin followed by two
washes in PBS, and mean cellular fluorescence was detected using a high-throughput Intellicyte iQue flow cytometer (Sartorius).
Antibody reactivity against each mutant S protein clone was calculated relative to wild-type S protein reactivity by subtracting the
signal from mock-transfected controls and normalizing to the signal from wild-type S-transfected controls. Mutations within clones
were identified as critical to the mAb epitope if they did not support reactivity of the test mAb but supported reactivity of other SARSCoV-2 antibodies. This counter-screen strategy facilitates the exclusion of S protein mutants that are locally misfolded or have an
expression defect.
Cell-surface binding to full- length S protein, variant S proteins, or S2 domain protein
A plasmid encoding the S protein C terminus S2 region (starting at residue S685) was transfected into HEK293T cells arrayed in a 384well plate and allowed to express for 22 h. Cells transfected with vector alone acted as negative controls. MAbs were screened over a
range of concentrations, 4 replicates for each mAb concentration, as described for epitope mapping. Fluorescence values were
background subtracted.
ELISA binding assay for serum analysis
To assess serum reactivity, 384-well microtiter plates were coated with purified recombinant SARS-CoV-2 S6Pecto at 4 c overnight.
Plates were blocked with blocking buffer (2% non-fat dry milk and 2% normal goat serum in DPBS containing 0.05% Tween-20) for 1
h. Serum was diluted 1:75 in blocking buffer, and then diluted three-fold serially 15 times, and added to wells. Binding was detected
with goat anti-human IgG conjugated with horseradish peroxidase and TMB substrate. The reaction was quenched with 1N hydrochloric acid once color was developed. The absorbance was measured at 450 nm using a spectrophotometer (Biotek).
Plasmablasts isolation and flow cytometric analysis
Blood was collected into tubes containing heparin. To assess plasmablasts frequency in PBMCs for analytical flow cytometric
studies, PBMCs were enriched from whole blood (day 10 after first, and day 7 after second vaccination) using direct PBMCs isolation
kit (StemCell Technologies). For singe-cell antibody secretion and paired antibody sequencing studies, plasmablasts were enriched
from the whole blood (day 7 after second vaccination) by negative selection using custom direct human plasmablasts isolation kit
containing paramagnetic beads and antibodies for negative selection (StemCell Technologies). Enriched cells were stained
30 min on ice in a RoboSep buffer (StemCell Technologies) containing following phenotyping antibodies; anti-CD19-FITC (1:20
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dilution, eBioscience), anti-CD27-APC (1:20 dilution), and anti-CD38-PE (1:25 dilution, BD Biosciences), and then analyzed by flow
cytometry using an SH800 cell sorter (Sony). A DAPI stain was used as a viability dye to exclude dead cells. Plasmablasts were identified as DAPI-CD19loCD27hiCD38hi cells. Approximately 40,000 and 6,000 plasmablasts were FACS-sorted in a bulk for paired
antibody sequencing and single-cell antibody secretion studies, respectively.
Generation of antibody variable-gene libraries from single plasmablasts
For paired antibody sequencing, cells were resuspended into DPBS containing 0.04% non-acetylated BSA, split into four replicates,
and separately added to 50 mL of RT Reagent Mix, 5.9 mL of Poly-dt RT Primer, 2.4 mL of Additive A and 10 mL of RT Enzyme Mix B to
complete the Reaction Mix as per the vendor’s protocol. The reactions then were loaded onto a Chromium chip (10x Genomics).
Chromium Single Cell V(D)J B Cell-enriched libraries were generated, quantified, normalized and sequenced according to the
User Guide for Chromium Single Cell V(D)J Reagents kits (CG000086_REV C). Amplicons were sequenced on an Illumina Novaseq
6000, and data were processed using the CellRanger software v3.1.0 (10X Genomics).
Single-cell antibody secretion analysis using Beacon instrument
FACS-purified plasmablasts were resuspended in plasmablast survival medium that promotes antibody secretion and assessed for
reactivity of secreted antibodies using the 11k chip on Beacon optofluidic instrument (Berkley Lights) as previously described (Zost
et al., 2020b). Single cell-antibody secretion binding assay was performed as previously described (Zost et al., 2020b) using SARSCoV-2 S6Pecto- and SARS-CoV-2 RBD-coated beads.
ELISpot assay
Direct enzyme-linked immunosorbent spot (ELISpot) assay was performed to enumerate plasmablasts present in the PBMC samples
secreting IgG, IgM, or IgA antibodies reacting with either SARS-CoV-2-S6Pecto protein or influenza A/Darwin/42/2020 H1N1 hemagglutinin protein (as a negative control). Briefly, 96-well ELISpot MSIP plates (Millipore) were activated with 100 mL 100% methanol/
well for 10 s, washed three times with 1 3 DPBS, coated overnight either with 100 mL of 2 mg/mL of SARS-CoV-2-S6Pecto or influenza
HA protein in PBS overnight at 4 C. Plates were washed three times with 1 3 DPBS and blocked by incubation with RPMI containing
10% FCS at 37 C for 2 h. Enriched plasmablasts or FACS-sorted plasmablasts were added to the plates and incubated 18-24 h at
37 C. Plates were washed with PBS and then PBS containing 0.05% Tween, and then incubated with either goat anti-human
IgG-HRP conjugated antibodies (Southern Biotech), goat anti-human IgA-HRP conjugated antibodies (Southern Biotech), or goat
anti-human IgM-HRP conjugated antibodies (Southern Biotech) for 2 h at room temperature. After washing three times with PBS containing 0.05% Tween/1% BSA, plates were developed using 3-amino-9-ethyl-carbazole (AEC) substrate (Sigma). The developed
plates were scanned, and spots were analyzed using an automated ELISpot counter (Cellular Technologies Ltd.). Plasmablasts or
sorted plasmablasts from PBMCs were added to the plates and incubated 18-24 h at 37 C. Plates were washed with PBS and
then PBS containing 0.05% Tween, and then incubated with either goat anti-human IgG-HRP conjugated antibodies (Southern
Biotech, catalog no. 2040-05), goat anti-human IgA-HRP conjugated antibodies (Southern Biotech, catalog no. 2050-05), or goat
anti-human IgM-HRP conjugated antibodies (Southern Biotech, catalog no. 2020-05) for 2 h at room temperature. After washing
three times with PBS containing 0.05% Tween/1% BSA, plates were developed using 3-amino-9-ethyl-carbazole (AEC) substrate
(Sigma). The developed plates were scanned and spots were analyzed using an automated ELISpot counter (Cellular Technologies
Ltd.).
QUANTIFICATION AND STATISTICAL ANALYSIS
The descriptive statistics mean ± SEM or mean ± SD were determined for continuous variables as noted. Virus titers in the tissues
were compared using one-way ANOVA with Turkey’s post-test. Curves for antibody binding and neutralization were fitted after log
transformation of antibody concentrations using non-linear regression analysis. Technical and biological replicates are indicated in
the figure legends. Statistical analyses were performed using Prism v8.4.3 (GraphPad).
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Figure S1. Controls for ELISA and neutralization assays, Related to Figure 2.
a. Positive or negative controls used for testing antibody binding in ELISA to SARS-CoV2-S6Pecto, SARSCoV-1 S2Pecto, or SARS-CoV-2 RBD proteins. The positive control antibody COV2-2381 binds to SARSCoV-2 S2Pecto and RBD but not to SARS-CoV-1 S2Pecto, and the positive control antibody rCR3022 also
binds to SARS-CoV-1 S2Pecto.
b. Positive or negative controls used for replication-competent chimeric VSV neutralization assays. COV22381 was used as a positive control for SARS-CoV-2 WT and D614G, whereas rCR3022 was used as a
positive control for SARS-CoV-1.
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Figure S2. Staining of dsRNA intensity, Related to Figure 2. Staining of dsRNA intensity split into DAPI
stain, dsRNA stain, and the two merged for each antibody group.

a. Staining for Group 1 antibodies.
b. Staining for Group 2 antibodies.
c. Staining for Group 3 antibodies.
d. Staining for control antibodies. 2D2247 is used as a negative control antibody. COV2-213043 is used as a
positive control antibody.
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10

Figure S3. Antibody binding to cell surface displayed variant S protein, Related to Figure 2. All public
clonotypes were tested against all variants listed, starting at 1 µg/mL. 1A9 from Genetex, an anti-S2 nonconformational antibody, was used as a control to test for spike protein expression.
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Figure S4. Negative stain electron microscopy complexes of each public clonotype, Related to Figure 3.
a. Negative stain EM of SARS-CoV-2 S6Pecto protein in complex with Fab forms of COV2-2002 or COV22333.
b. Negative stain EM of SARS-CoV-2 S6Pecto protein in complex with Fab forms of COV2-2164 or
CnC2t1p1_B10.
c. Negative stain EM of SARS-CoV-2 S6Pecto protein in complex with Fab forms of COV2-2531 or C126.
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Figure S5. Control reagents for detection of antibody binding to membrane-anchored S
protein in cell-surface antigen-display assays, Related to Figures 2 and 3.
Gating strategy used for cell-surface antigen-display experiment. The first gate is for all cells, the
a.
second gate is for infected cells, and the third gate is for antibody binding to infected cells.
b.
Controls used for cell-surface antigen-display antibody binding experiment. Cell-only control in
shown in light grey. The unrelated mAb DENV 2D22 was used as an antibody negative control, shown in
dark grey. The mAb COV2-2381 shown in dark blue and mAb rCR3022 shown in turquoise were used as
positive antibody controls.
c.
Histogram of data obtained using infected or uninfected cells. Infected cells are shown in light grey,
and uninfected cells are shown in dark grey.
d.
Group 1, 2, or 3 antibody binding to infected cells. The antibody concentration used was 10 µg/mL
for all antibodies.
e.
Group 1, 2, or 3 germline-revertant antibody binding to infected cells. The antibody concentration
used was 10 µg/mL for all antibodies.
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Figure S6. Primary data for alanine mutagenesis screening, Related to Figure 3. Binding values for mAbs
on the SARS-CoV-2 S protein alanine scan library. The binding values at critical mutant clones for
a. Group 1 (COV2-2002 in light purple and COV2-2333 in dark purple) and Group 2 (COV2-2164 in pink
and CnC2t1p1_B10 in red )antibodies are shown as a percentage of mAb binding to wild-type (WT)
SARS-CoV-2 spike protein and are plotted with the range (highest-minus lowest binding value) of at least
two measurements.
b. Group 3 (COV2-2531 in light orange and C126 in dark orange) antibodies are shown as a percentage of
mAb binding to wild-type (WT) SARS-CoV-2 spike protein and are plotted with the range (highest-minus
lowest binding value) of at least two measurements.
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Virus

Amino acid sequence of the RBD protein, at the indicated positions

SARS-CoV-1
SARS-CoV-2

306 RVVPSGDVVRFPNITNLCPFGEVFNATKFPSVYAWERKKISNCVADYSVL 355
319 RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVL 368

SARS-CoV-1
SARS-CoV-2

356 YNSTFFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVI 405
369 YNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKI 418

SARS-CoV-1
SARS-CoV-2

406 ADYNYKLPDDFMGCVLAWNTRNIDATSTGNHNYKYRYLRHGKLRPFERDI 455
419 ADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDI 468

SARS-CoV-1
SARS-CoV-2

456 SNVPFSPDGKPCTP-PALNCYWPLNDYGFYTTTGIGYQPYRVVVLSFELL 504
469 STEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELL 518

SARS-CoV-1
SARS-CoV-2

505 NAPATVCGPKLSTDLIKNQCVNF
519 HAPATVCGPKKSTNLVKNKCVNF

CR3022 epitope
COV2-2531 critical residues
C126 critical residues

Figure S7. Overlay of CR3022 structure with Group 3 antibodies when bound to RBD, Related to Figure 3.
a. The structures for the RBD domains for both SARS-CoV-2 and SARS-CoV-1 were overlaid. The epitope
of rCR3022 is highlighted in orange (from Yuan et al.). Light orange dots denote the binding residues for
mAb COV2-2531, and dark orange dots denote the binding residues for C126. Figure adapted from
previous study48.

Extended data Fig.

Group 1 Germline Revertant:
HC: EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANIKQDGSEKYY

VDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVGSSSWYFDYWGQGTLVTVSS

LC:

SYELTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGIPER
FSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTGVFGGGTKLTV

Group 2 Germline Revertant:
HC: QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANY

AQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARTSHYDSSGSYFEYWGQGTLVTVSS

LC: EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPA

RFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPSLTFGGGTKVEI

Group 3 Germline Revertant:
HC: QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYN

PSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARATWLRDAFGIWGQGTMVTVSS

LC: NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVP

DRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNVVFGGGTKLTVL

Figure S8. Germline revertant sequences for each public clonotype group, Related to Figure 4. The
corresponding heavy and light chain germline revertant sequences of each public clonotype are listed.

